12:00 AM
Oct 27, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MAXY-G34: Phase IIb delayed

Maxygen said that in connection with its announced cost-cutting measures and headcount reduction the start of Phase IIb trials...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >